Phase 3 - Evaluation of Veregen® 10% Ointment as New Herbal Topical Treatment for Actinic Keratosis

PHASE3RecruitingINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

September 4, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

November 30, 2027

Conditions
Actinic Keratosis of Face and Scalp
Interventions
DRUG

Topical treatment

Self-treatment of patients with ointment of a pre-defined treatment area (TA) following a treatment period of 12 weeks and a 4-weeks post-treatment (PT) period (i.e., after 16 weeks at most in patients without complete clearance at the end of the treatment (EoT) period).

Trial Locations (1)

Unknown

RECRUITING

Aresus Pharma GmbH, Strausberg

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Aresus Pharma GmbH

INDUSTRY

NCT07137819 - Phase 3 - Evaluation of Veregen® 10% Ointment as New Herbal Topical Treatment for Actinic Keratosis | Biotech Hunter | Biotech Hunter